Price Alert

Dianthus Therapeutics Inc... (DNTH)

NASDAQ: DNTH · Real-Time Price · USD

26.50

1.84 (7.46%)

At close: Sep 05, 2025, 3:59 PM

26.50

0.00%

After-hours: Sep 05, 2025, 04:10 PM EDT

7.46% (1D)

Bid	25.09
Market Cap	852.99M
Revenue (ttm)	4.85M
Net Income (ttm)	-114.75M
EPS (ttm)	-3.32
PE Ratio (ttm)	-7.98
Forward PE	-6.65
Analyst	Buy

Ask	28
Volume	676,380
Avg. Volume (20D)	356,109
Open	25.15
Previous Close	24.66
Day's Range	24.48 - 27.03
52-Week Range	13.37 - 32.27
Beta	1.46

About DNTH

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DNTH

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DNTH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Dianthus Therapeutics Inc. is scheduled to release its earnings on Nov 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

News

1 month ago · zacks.com

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.51 per share a year ago.

1 month ago · fool.com

Dianthus (DNTH) Q2 Loss Widens 80%

Dianthus Therapeutics (DNTH -6.08%), a clinical-stage biotech developing therapies for autoimmune neuromuscular diseases, reported second quarter results on August 7, 2025. Net loss per share (GAAP) w...

4 weeks ago · zacks.com

Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline

Dianthus Therapeutics, Inc. (DNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.